2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2373

Frequency of Antinuclear (ANA), Myositis-Specific (MSA) and Myositis-Associated Antibodies (MAA) in Patients with Idiopathic Inflammatory Myopathies (IIM) from Mexico, Central and South America Centers: Data from the Panlar Myositis Study Group.
Abstract Number: 131

Frequency of Lipid Testing and Management Among Rheumatoid Arthritis Patients Compared to the General Population and Patients with Diabetes
Abstract Number: 3062

Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia
Abstract Number: 393

From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients
Abstract Number: 392

From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Abstract Number: 1805

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Abstract Number: 1867

Functional Androgen Receptor Variants Associated with Greater Damage in Systemic Lupus Erythematosus
Abstract Number: 3202

Functional Anti-Muscarinic Receptor-3 Monoclonal Antibodies Derived from Salivary Gland in Patients of Sjögren’s Syndrome
Abstract Number: 1360

Functional Consequences of NOD2 Gene Variants in Patients with NOD2-Associated Autoinflammatory Disease
Abstract Number: 3267

Functional Disability in Adolescents Is Predicted By Self-Report of Sleep Problems, Depressive Symptoms, Low Physical Activity and Worst Pain Intensity Levels
Abstract Number: 2556

Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of CD4+ T-Cell Mediated Autoimmune Arthritis
Abstract Number: 2016

Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging
Abstract Number: 785

Further Validation of Simple Index As a Simple Disease Activity Assessment Tool for SLE
Abstract Number: 1173

G Protein Coupled Receptor Kinase 3 Regulation of Inflammatory Arthritis
Abstract Number: 1256

Gas Chromatography/Time-of-Flight-Mass Spectrometry-Based Metabolomic Profiling in Cultured Fibroblast-like Synoviocytes from Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].